Enanta Pharmaceuticals (ENTA)
Develops oral RSV antivirals and immunology drugs funded by AbbVie HCV royalties.
$12.08
vs last close−0.34 (−2.72%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 94.78% | 27.56M shares | |
|---|---|---|---|
| 127 holders · as of Jun 30, 2026 | |||
| Insiders | 10.91% | 3.17M shares | |
| 10 holders · as of Aug 10, 2026 | |||
| Strategic holders | 12.02% | 3.49M shares | |
| 1 holder · as of Nov 7, 2025 | |||
| Adds to | 117.71% | ||
29.08M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 117.71%; nothing is left for Other.
13F, as of Jun 30, 2026
127 holders · 27.56M shares · 15 new positions · 61 increased · 38 reduced · 23 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 3.65M | 12.57% | +3.65Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 3.24M | 11.16% | +140.7K | Aug 7, 2026 |
| Krensavage Asset Management, LLC | 2.87M | 9.86% | 0 | Aug 14, 2026 |
| Farallon Capital Management LLC | 2.42M | 8.32% | −453.7K | Aug 14, 2026 |
| Deep Track Capital, LP | 1.44M | 4.97% | −512.7K | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 1.34M | 4.62% | +1.29M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.21M | 4.17% | +33.7K | Aug 13, 2026 |
| Spruce Street Capital LP | 1.09M | 3.74% | +156.1K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 12.10% | 3.49M | 13G | Nov 7, 2025 |
| BlackRock, Inc. | 7.80% | 1.67M | 13G | Apr 17, 2025 |
| Jay R. Luly, Ph.D. | 7.70% | 1.70M | 13D | Feb 14, 2025 |
| Deep Track Capital, LP | 6.78% | 1.96M | 13G | Feb 13, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Dec 5, 2025 | Jay R. Lulydirector, officer: President and CEO | Sale | 4,743 | $14.23 | 858,026 |
| Dec 5, 2025 | Yat Sun Orofficer: Chief Scientific Officer | Sale | 2,390 | $14.23 | 371,392 |
| Dec 5, 2025 | Tara Lynn Kiefferofficer: Chief Product Strategy Officer | Sale | 2,106 | $14.23 | 30,620 |
| Dec 5, 2025 | Brendan Luuofficer: Chief Business Officer | Sale | 1,394 | $14.23 | 38,329 |
| Dec 5, 2025 | Scott T. Rottinghausofficer: Chief Medical Officer | Sale | 798 | $14.23 | 21,792 |
| Dec 5, 2025 | Harry R. III Troutofficer: See Remarks | Sale | 542 | $14.23 | 16,348 |
| Dec 5, 2025 | Kathleen S. Cappsofficer: See Remarks | Sale | 323 | $14.23 | 8,377 |
| Dec 2, 2025 | Harry R. III Troutofficer: See Remarks | Sale | 380 | $13.96 | 16,890 |
| Dec 2, 2025 | Kathleen S. Cappsofficer: See Remarks | Sale | 207 | $13.96 | 8,700 |
House and Senate disclosures
Not reported.